Clinical practice-changing trials: the HERA study paradigm.
Authors : Zardavas D, Ades F, de Azambuja E
Year : 2013
Journal : Expert Rev Anticancer Ther
Volume : 13(11)
Pages : 1249-56
Discrepancies in cancer incidence and mortality and its relationship to health expenditure in the 27 European Union member states.
Authors : Ades F, Senterre C, de Azambuja E, Sullivan R, Popescu R, Parent F, Piccart-Gebhart M
Year : 2013
Journal : Ann Oncol
Volume : 24(11)
Pages : 2897-902
Pattern of Rash, Diarrhea, and Hepatic Toxicities Secondary to Lapatinib and Their Association With Age and Response to Neoadjuvant Therapy: Analysis From the NeoALTTO Trial.
Authors : Azim HA, Agbor-Tarh D, Bradbury I, Dinh P, Baselga J, Di Cosimo S, Greger JG, Smith I, Jackisch C, Kim SB, Aktas B, Huang CS, Vuylsteke P, Hsieh RK, Dreosti L, Eidtmann H, Piccart-Gebhart M, de Azambuja E
Year : 2013
Journal : J. Clin. Oncol.
Volume : 31(36)
Pages : 4504-11
Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: A sub-study from the NeoALTTO phase III trial.
Authors : Azim HA, Rothé F, Aura CM, Bavington M, Maetens M, Rouas G, Gebhart G, Gamez C, Eidtmann H, Baselga J, Piccart-Gebhart M, Ellis C, Vuylsteke P, Cure H, Domont J, Ferro A, Toral-Peña JC, de Azambuja E, Sotiriou C, Di Cosimo S, Ignatiadis M
Year : 2013
Journal : Breast
Volume : 22(6)
Pages : 1060-5
Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial.
Authors : Oakman C, Francis PA, Crown J, Quinaux E, Buyse M, de Azambuja E, Margeli Vila M, Andersson M, Nordenskjöld B, Jakesz R, Thürlimann B, Gutiérrez J, Harvey V, Punzalan L, Dell orto P, Larsimont D, Steinberg I, Gelber Rd, Piccart-Gebhart M, Viale G, Di Leo A
Year : 2013
Journal : Ann Oncol
Volume : 24(5)
Pages : 1203-11
Analysis of Regional Timelines To Set Up a Global Phase III Clinical Trial in Breast Cancer: The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Experience.
Authors : Metzger-Filho O, de Azambuja E, Bradbury I, Saini KS, Bines J, Simon SD, Dooren VV, Aktan G, Pritchard KI, Wolff AC, Smith I, Jackisch C, Lang I, Untch M, Boyle F, Xu B, Baselga J, Perez EA, Piccart-Gebhart M
Year : 2013
Journal : Oncologist
Volume : 18(2)
Pages : 134-40
Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98.
Authors : Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, de Azambuja E, Quinaux E, Di Leo A, Michiels S, Piccart-Gebhart M, Sotiriou C
Year : 2013
Journal : J. Clin. Oncol.
Volume : 31(7)
Pages : 860-7
CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).
Authors : Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, Láng I, Wardley A, Lichinitser M, Sanchez RI, Müller V, Dodwell D, Gelber Rd, Piccart-Gebhart M, Cameron D
Year : 2013
Journal : Lancet Oncol
Volume : 14(3)
Pages : 244-8
Impressive response to eribulin in endocrine- and chemotherapy resistant metastatic breast cancer
Authors : Vanderbeeken MC, de Azambuja E
Year : 2013
Journal : Belgian J Medical Oncology
Volume : 7(1)
Pages : 27-30
Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01).
Authors : Azim HA, Metzger-Filho O, de Azambuja E, Loibl S, Focant F, Gresko E, Arfi M, Piccart-Gebhart M
Year : 2012
Journal : Breast Cancer Res. Treat.
Volume : 133(1)
Pages : 387-91
Dissecting the heterogeneity of triple-negative breast cancer.
Authors : Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA, Ellis P, Di Leo A, Baselga J, Sotiriou C, Piccart-Gebhart M
Year : 2012
Journal : J. Clin. Oncol.
Volume : 30(15)
Pages : 1879-87
Targeted therapies in breast cancer: are heart and vessels also being targeted?
Authors : Criscitiello C, Metzger-Filho O, Saini KS, de Castro G, Diaz M, La Gerche A, de Azambuja E, Piccart-Gebhart M
Year : 2012
Journal : Breast Cancer Res
Volume : 14(3)
Pages : 209
Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer.
Authors : Zardavas D, Bozovic-Spasojevic I, de Azambuja E
Year : 2012
Journal : Curr Opin Oncol
Volume : 24(6)
Pages : 612-22
Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries.
Authors : Saini KS, Taylor C, Ramirez AJ, Palmieri C, Gunnarsson U, Schmoll HJ, Dolci SM, Ghenne C, Metzger-Filho O, Skrzypski M, Paesmans M, Ameye L, de Azambuja E, Piccart-Gebhart M
Year : 2012
Journal : Ann Oncol
Volume : 23(4)
Pages : 853-859
Chemoprevention for breast cancer.
Authors : Bozovic-Spasojevic I, de Azambuja E, McCaskill-Stevens W, Dinh P, Cardoso F
Year : 2012
Journal : Cancer Treat Rev
Volume : 38(5)
Pages : 329-339
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines.
Authors : Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, Criscitiello C, Goldhirsch A, Cipolla C, Roila F
Year : 2012
Journal : Ann Oncol
Volume : 23 Suppl 7
Pages : vii155-66
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.
Authors : Fernández-Cuesta L, Oakman C, Falagan-Lotsch P, Smoth KS, Quinaux E, Buyse M, Dolci MS, de Azambuja E, Hainaut P, + collaborators (among others :, Larsimont D, Piccart-Gebhart M, Olivier M
Year : 2012
Journal : Breast Cancer Res
Volume : 14(3)
Pages : R70
Treatment Options in Anthracycline and/or Taxane Pretreated Patients with Metastatic Breast Cancer.
Authors : Pugliano L, de Azambuja E
Year : 2012
Journal : Onkologie
Volume : 35(9)
Pages : 476-8
Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence.
Authors : Rossari JR, Metzger-Filho O, Paesmans M, Saini KS, Gennari A, de Azambuja E, Piccart-Gebhart M
Year : 2012
Journal : J Oncol
Volume : 2012
Pages : 417673
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
Authors : Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber Rd, Piccart-Gebhart M
Year : 2012
Journal : Lancet
Volume : 379(9816)
Pages : 633-40